Insider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells $16,173.60 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 879 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $18.40, for a total value of $16,173.60. Following the sale, the insider now owns 93,444 shares of the company’s stock, valued at $1,719,369.60. This represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pacira BioSciences Stock Performance

PCRX stock opened at $18.58 on Thursday. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.81. The stock has a market capitalization of $857.89 million, a price-to-earnings ratio of -9.15 and a beta of 0.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock’s fifty day moving average is $18.15 and its two-hundred day moving average is $17.79.

Analyst Upgrades and Downgrades

PCRX has been the topic of several analyst reports. Barclays dropped their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research report on Friday, November 8th. Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada upped their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $23.50.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently bought and sold shares of PCRX. Bank of New York Mellon Corp raised its holdings in shares of Pacira BioSciences by 0.5% during the second quarter. Bank of New York Mellon Corp now owns 400,002 shares of the company’s stock valued at $11,444,000 after buying an additional 2,141 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Pacira BioSciences by 6.6% in the second quarter. Rhumbline Advisers now owns 159,467 shares of the company’s stock worth $4,562,000 after purchasing an additional 9,869 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Pacira BioSciences by 18.7% during the second quarter. Victory Capital Management Inc. now owns 87,639 shares of the company’s stock valued at $2,507,000 after purchasing an additional 13,776 shares during the period. LSV Asset Management bought a new stake in shares of Pacira BioSciences during the second quarter valued at about $462,000. Finally, Quest Partners LLC acquired a new stake in Pacira BioSciences in the second quarter worth about $113,000. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.